]>
IRCT20171205037759N2 IRCT 2026-10-22 The Iran National Science Foundation Effectiveness of Sprint Exercise Snacks on Cardiometabolic Health and Fitness in Female Students The Effect of Six Weeks of Sprint Exercise Snacks on Cardiometabolic Health and Cardiorespiratory Fitness in Inactive Overweight and Obese Female University Students: A Randomized Controlled Trial 2026-11-11 anticipated 44 Pending https://irct.ir/trial/94200 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Participants are allocated to the intervention and control groups using block randomization. The unit of randomization in this study is individual. To achieve balance between groups regarding key variables such as age and baseline body mass index, stratified randomization is used based on these variables. The random sequence is generated using statistical software, whereby numbers 1 to 44 are randomly assigned to the two groups. For allocation concealment, group assignment is performed by a third party not involved in the screening or intervention process and is kept in sealed, opaque envelopes. These envelopes are opened only upon participant entry into the study and after final confirmation of eligibility criteria. Furthermore, outcome assessors are blinded to the group allocation of participants, Blinding description: Due to the nature of the exercise intervention in this study, full blinding (double-blind or triple-blind) is not feasible. Participants are aware of their assigned group (intervention or control), and this awareness is fully and transparently disclosed in the informed consent form. The principal investigator is also aware of group allocation due to responsibility for coordinating the protocol and supervising exercise sessions. Healthcare personnel and exercise practitioners (those responsible for implementing the protocol) are also aware of participants' group status. However, blinding is applied at two levels as follows: First, outcome assessors (including those responsible for anthropometric measurements, blood sampling, physical fitness tests, and questionnaire administration) are blinded to participants' group allocation and receive data only with identification codes. Second, the data analyst is also blinded to group allocation and performs statistical analyses on coded data without knowledge of group names. No independent Data Safety and Monitoring Committee (DSMB) was established in this study. Additionally, individuals responsible for drafting the manuscript will be aware of group allocation, but interpretation of results will be based on blinded statistical analyses. N/A Overweight and Obesity. Intervention 1: Intervention group: Performing a 6-week sprint exercise snack protocol, three non-consecutive days per week. On each training day, three exercise snacks are performed 20 to 30 minutes before breakfast, lunch, and dinner. Each snack consists of several consecutive micro-bouts, with each micro-bout comprising 10 seconds of activity at the highest safe and technically acceptable speed followed by 20 seconds of recovery (standing or very slow walking). The number of micro-bouts per snack increases from 3 in weeks 1-2 to 4 in weeks 3-4 and 5 in weeks 5-6. Activity type: rapid, low-impact alternating step-ups with body weight on a 15-cm fixed platform. Exercise intensity is controlled using the Borg Category-Ratio 10 (CR-10) perceived exertion scale, with a target intensity of 8 to 9 out of 10 at the end of each snack. The total active high-intensity exercise time across the entire intervention is 39 minutes. Intervention 2: Control group: Maintaining usual lifestyle and refraining from any new or structured exercise program during the study period. Participants in this group are advised to maintain their usual dietary and physical activity patterns as much as possible and to avoid starting any new exercise program outside the study. After completion of the study period and post-test data collection, control group members will be offered the exercise protocol (exercise snacks). Yes - There is a plan to make this available What will be shared: داده‌های فردی ناشناس‌شده شرکت‌کنندگان (IPD)، پروتکل مطالعه، نقشه آنالیز آماری، فرم رضایت‌نامه آگاهانه و دیکشنری داده‌ها. داده‌های فردی شامل اطلاعات جمعیت‌شناختی، شاخص‌های آنتروپومتریک، متغیرهای خونی، فشار خون و نتایج آزمون‌های آمادگی جسمانی خواهد بود که به طور کامل غیرقابل شناسایی خواهند شد When: It will begin 6 months after publication of the primary results and will continue for 5 years. To whom: Academic researchers and investigators affiliated with scientific and research institutions Conditions: Data will be used solely for scientific and research purposes (e.g., meta-analysis or secondary data analysis). Requestors must submit a brief research proposal and sign a confidentiality agreement. Commercial use of the data is prohibited. Where to obtain: Dr. Khalil ollah Monikh (Principal Investigator), Farhangian University of Zanjan. Email: kh.moonikh@cfu.ac.ir. Phone: +98 912 441 1878. How to obtain: The applicant sends a request form to the principal investigator's email. The request is reviewed by the research team (within a maximum of 2 weeks). Upon approval, a Data Transfer Agreement (DTA) is signed, and de-identified data will be provided to the applicant via a secure link. Comments:
public Raoof Negaresh
No. 9, West Torbat Street, Saadi Neighborhood
Zanjan Iran (Islamic Republic of) 6316584751 +98 24 5338 1001 raoof.negaresh@cfu.ac.ir Farhangian Univeristy scientific Raoof Negaresh
No. 9, West Torbat Street, Saadi Neighborhood
Zanjan Iran (Islamic Republic of) 6316584751 +98 24 5338 1001 raoof.negaresh@cfu.ac.ir Farhangian Univeristy Iran (Islamic Republic of) Female university students aged 19 to 30 years Resident of Al-Zahra Female Dormitory at Farhangian University of Zanjan Body Mass Index (BMI) between 24.9 and 34.9 (overweight and class I obesity) Low physical activity level based on IPAQ-SF (less than 600 MET-minutes per week) No medical contraindication for vigorous physical activity No known cardiovascular, metabolic, or neuromuscular diseases that could affect the study results Ability to perform brisk walking without limitation 19 years 30 years Female Pregnancy or lactation Active cardiovascular disease or musculoskeletal disease that prevents vigorous physical activity Use of medications affecting metabolism (such as statins or anti-diabetic drugs) Smoking and alcohol consumption Participation in a regular exercise program within 3 months prior to study initiation Acute illness at the time of screening Behavior N/A Intervention group: Performing a 6-week sprint exercise snack protocol, three non-consecutive days per week. On each training day, three exercise snacks are performed 20 to 30 minutes before breakfast, lunch, and dinner. Each snack consists of several consecutive micro-bouts, with each micro-bout comprising 10 seconds of activity at the highest safe and technically acceptable speed followed by 20 seconds of recovery (standing or very slow walking). The number of micro-bouts per snack increases from 3 in weeks 1-2 to 4 in weeks 3-4 and 5 in weeks 5-6. Activity type: rapid, low-impact alternating step-ups with body weight on a 15-cm fixed platform. Exercise intensity is controlled using the Borg Category-Ratio 10 (CR-10) perceived exertion scale, with a target intensity of 8 to 9 out of 10 at the end of each snack. The total active high-intensity exercise time across the entire intervention is 39 minutes. Control group: Maintaining usual lifestyle and refraining from any new or structured exercise program during the study period. Participants in this group are advised to maintain their usual dietary and physical activity patterns as much as possible and to avoid starting any new exercise program outside the study. After completion of the study period and post-test data collection, control group members will be offered the exercise protocol (exercise snacks). Maximal oxygen consumption (VO2max) in ml/kg/min, measured using the Rockport 1-Mile Walk Test. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Rockport 1-Mile Walk Test; the participant walks one mile at the highest safe speed, and the time to complete the distance and heart rate immediately after the test are recorded. Body fat percentage, measured using a body composition analyzer. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: InBody-270 body composition analyzer; measurements are performed in a fasting state, without heavy clothing, and at least 24 hours after the last vigorous activity. Waist circumference in centimeters, measured using a non-elastic tape measure. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Non-elastic tape measure; measurements are taken in a standing position at the end of a normal expiration, at the midpoint between the lowest rib and the iliac crest, with an accuracy of 0.1 cm, and the average of two consecutive measurements is recorded. Waist-to-height ratio, calculated by dividing waist circumference (cm) by height (cm). Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Waist-to-height ratio is calculated by dividing waist circumference (measured with a non-elastic tape measure) by height (measured with a wall-mounted stadiometer). Blood lipid profile including total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides in milligrams per deciliter, measured by enzymatic method. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Venous blood samples are collected after 10 to 12 hours of fasting between 7:00 and 9:00 AM; samples are centrifuged in tubes containing EDTA anticoagulant, and the separated serum is analyzed for total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides using laboratory kits and enzymatic method. Systolic and diastolic blood pressure in millimeters of mercury, measured using a digital upper-arm blood pressure monitor. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Omron M6 Comfort digital upper-arm blood pressure monitor; measurements are taken after 10 minutes of rest in a seated position with the arm supported at heart level, and the average of two measurements taken one minute apart is recorded. Fasting blood glucose in milligrams per deciliter, measured by enzymatic method. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: Venous blood samples are collected after 10 to 12 hours of fasting between 7:00 and 9:00 AM; the sample is centrifuged in a tube containing EDTA anticoagulant, and the separated serum is analyzed for fasting blood glucose using a laboratory kit and enzymatic method. Insulin resistance index, calculated using the formula: (fasting insulin multiplied by fasting glucose) divided by 405. Timepoint: Measured at two time points: baseline (before the intervention) and at the end of week six (after completion of the intervention). Method of measurement: The insulin resistance index is calculated using a formula based on fasting insulin (measured by enzyme-linked immunosorbent assay) and fasting blood glucose (measured by enzymatic method). The Iran National Science Foundation Approved 2026-08-31 کارگروه اخلاق در پژوهش پژوهشگاه علوم ورزشی No. 3, 5th St., Mir Emad St., Motahari Ave. Tehran Tehran Iran (Islamic Republic of)